Form 4: Brainstorm Cell Therapeutics Director Acquires 24,000 Shares of Restricted Stock Units

A Brainstorm Cell Therapeutics director, Menghisteab Bairu, acquired 24,000 restricted stock units on January 1, 2025.

Summary

• Menghisteab Bairu, a director at Brainstorm Cell Therapeutics Inc., acquired 24,000 shares of restricted stock units (RSUs) on January 1, 2025.
• The RSUs were awarded under the company's 2014 Stock Incentive Plan.
• 50% of the RSUs vested immediately on the grant date, and the remaining 50% will vest six months later, provided Mr. Bairu remains employed by the company.
• The acquisition was reported in a Form 4 filing with the SEC.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it reflects standard compensation practices and aligns director interests with the company's success. There is no indication of any negative issues.

Positives

• The acquisition of RSUs by a director indicates confidence in the company's future.
• The vesting schedule incentivizes the director to remain with the company.

Future Outlook

The remaining 50% of the RSUs will vest in six months, contingent on the director's continued employment.

Industry Context

This is a standard practice for compensating directors and aligning their interests with the company's performance in the biotechnology industry.

Comparison to Industry Standards

• Granting restricted stock units to directors is a common practice in the biotechnology industry.
• Vesting schedules, such as the one described, are typical for incentivizing long-term commitment from key personnel.
• Many biotech companies use similar stock incentive plans to attract and retain talent, including directors.

Stakeholder Impact

• The acquisition of RSUs by a director may be viewed positively by shareholders as it aligns the director's interests with the company's performance.
• The vesting schedule incentivizes the director to remain with the company, which can be beneficial for employees and other stakeholders.

Next Steps

• The remaining 50% of the RSUs will vest in six months if the director remains employed.

Key Dates

Keywords

restricted stock units, RSUs, stock incentive plan, director, insider trading, Brainstorm Cell Therapeutics, BCLI, equity compensation